Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer
- Michael L Maitland1, 3, 4Email author,
- Matthew R Levine1,
- Mario E Lacouture2, 7,
- Kristen E Wroblewski5,
- Christine H Chung8, 9,
- Ilyssa O Gordon6,
- Livia Szeto1,
- Gail Ratko10,
- Keyoumars Soltani2,
- Mark F Kozloff1, 10,
- Philip C Hoffman1,
- Ravi Salgia1, 3, 4,
- David P Carbone9,
- Theodore G Karrison4, 5 and
- Everett E Vokes1, 4
© Maitland et al.; licensee BioMed Central Ltd. 2014
Received: 29 April 2013
Accepted: 12 December 2013
Published: 4 January 2014
Candidate predictive biomarkers for epidermal growth factor receptor inhibitors (EGFRi), skin rash and serum proteomic assays, require further qualification to improve EGFRi therapy in non-small cell lung cancer (NSCLC). In a phase II trial that was closed to accrual because of changes in clinical practice we examined the relationships among candidate biomarkers, quantitative changes in tumor size, progression-free and overall survival.
55 patients with progressive NSCLC after platinum therapy were randomized to receive (Arm A) cetuximab, followed by pemetrexed at progression, or (Arm B) concurrent cetuximab and pemetrexed. All received cetuximab monotherapy for the first 14 days. Pre-treatment serum and weekly rash assessments by standard and EGFRi-induced rash (EIR) scales were collected.
43 patients (20-Arm A, 23-Arm B) completed the 14-day run-in. Median survival was 9.1 months. Arm B had better median overall (Arm B = 10.3 [95% CI 7.5, 16.8]; Arm A = 3.5 [2.8, 11.7] months P = 0.046) and progression-free survival (Arm B = 2.3 [1.6, 3.1]; Arm A = 1.6 [0.9, 1.9] months P = 0.11). The EIR scale distributed ratings among 6 rather than 3 categories but ordinal scale rash severity did not predict outcomes. The serum proteomic classifier and absence of rash after 21 days of cetuximab did.
Absence of rash after 21 days of cetuximab therapy and the serum proteomic classifier, but not ordinal rash severity, were associated with NSCLC outcomes. Although in a small study, these observations were consistent with results from larger retrospective analyses.
Clinicaltrials.gov Identifier NCT00203931
KeywordsPemetrexed Lung Cancer Cetuximab Rash EGFR Proteomics
The monoclonal antibody inhibitor of epidermal growth factor receptor (EGFR)- cetuximab adds modest benefit to front-line chemotherapy in patients with previously untreated advanced non-small cell lung cancer (NSCLC)[1, 2]. This benefit is cost-ineffective by reference standards [3, 4]. The role of tumor EGFR expression in predicting benefit from adding cetuximab in NSCLC is under investigation –. For the small molecule EGFR inhibitor (EGFRi) erlotinib in NSCLC, skin rash and serum proteomic assays were initially identified as candidate predictive biomarkers –. These findings suggested that non-tumor biomarkers might predict subsets of patients likely to benefit from administration of EGFRis, including cetuximab. A retrospective landmark time-point analysis in the BMS099 trial  and a pre-specified subset analysis in the FLEX  trial demonstrated better outcomes for patients who developed rash by the end of cycle 1 with cetuximab added to front-line therapy. These findings suggested that rash is a candidate predictive clinical biomarker for cetuximab in front-line NSCLC therapy but to validate the marker would require another large, randomized prospective study .
The scales for severity of rash from antineoplastic drugs are crude instruments for determining therapeutic decisions. The scales are structured to equate severity across the full spectrum of adverse events and are designed as tools for safe conduct of clinical trials. They are not validated or intended as biomarkers for treatment effects . To ascertain cetuximab-induced rash, Gatzemeier, et al. collapsed 20 different terms from the MEDRA 10.0 adverse event database . The prospective use of clinician detection of rash as a biomarker might require more structured assessment. The pathophysiology of the rash associated with EGFR inhibitors is most reminiscent of acne rosacea (rosacea), for which a validated severity scale has already been developed .
A serum mass spectrometry-based classifier assay segregates candidates for EGFRi therapy into “good” and “bad” prognosis groups . In multiple studies of EGFRis, the patients in the two groups had divergent survival patterns, but not in NSCLC patients treated with cytotoxic therapy, suggesting that the serum proteomic profile is a predictive rather than prognostic marker. In studies of erlotinib in NSCLC: for first-line treatment  and when combined with bevacizumab therapy  the assay again predicted survival differences. The assay performed similarly in multiple clinical studies of patients with squamous cell carcinoma of the head and neck and in colorectal cancer , including subsets of these patients treated with cetuximab. Although commercially available as VeriStrat® (Biodesix, Broomfield, USA), the assay has not been prospectively qualified as a predictive marker for EGFRi therapy.
We conducted a randomized, phase II trial in previously treated NSCLC patients that compared the concurrent and sequential administration of cetuximab and pemetrexed. A component of the trial was to conduct preliminary development of biomarkers for cetuximab. Specifically for this trial, we adapted the validated rosacea severity scale as an EGFRi-induced rash (EIR) scale for better differentiation than the ordinal CTCAE scale of rash assessments. Additionally, serial serum samples were collected and stored at -80°C. The randomization and 2-week run-in design of the trial enabled concurrent analysis of rash rating and the serum assay as candidate predictive markers for cetuximab therapy in NSCLC.
The trial closed prior to achieving its initially intended accrual goals. The original hypothesis to be tested by the trial was to determine in patients with NSCLC refractory to previous chemotherapy whether concomitant treatment with cetuximab and pemetrexed improved progression-free survival compared with cetuximab monotherapy. We estimated a sample of 40 patients per treatment group based on many assumptions, including a relatively modest difference in outcomes between the study arms. Our estimates were inaccurate, and patients who were randomized to the combination therapy arm had much better outcomes than patients in the monotherapy arm. Additionally, large clinical trials of pemetrexed revealed advantages to early initiation of pemetrexed after first-line therapy, and single-arm studies of cetuximab in unselected patients revealed no benefit to cetuximab monotherapy in this population. Therefore the study was closed after reaching half of its intended accrual. The preponderance of available evidence now supports that the administration of pemetrexed in the second-line treatment setting would be superior to cetuximab monotherapy. We report the results of this trial not to demonstrate a definitive assessment of the difference in the randomized treatment arms, but rather to provide the foundation for this biomarker development exercise.
The trial was intended to study pharmacodynamic biomarkers in unselected patients and collection of tumor tissue was not incorporated into the study design. But the study called for all patients to provide pre-treatment serum samples and to undergo standardized, prospective rash evaluations. There are many limitations to the successful development of valid clinically relevant biomarkers concurrently with novel anticancer agents. The need to collect material for markers prospectively, combined with the observation time required to accumulate outcome data with which to qualify biomarkers makes the process slow and expensive. In this manuscript we have examined the data from this trial with 3 goals: 1) to explore the use of quantitative changes in tumor burden at an early time-point in a trial as a measure of drug effect (rather than RECIST-based response or time to progression), 2) to determine whether the prospectively collected biomarker data in this trial are consistent with retrospective analyses of larger clinical trials, and 3) to perform a preliminary estimate of the value of intensive, quantitative rash assessments as a candidate biomarker for future studies of EGFR inhibitors.
The first patient enrolled in July 2005. The study closed to accrual in March 2008 with minimum 6-month follow-up. Eligible patients were ≥ 18 years with confirmed NSCLC not amenable to curative therapy. All patients were previously treated with at least one platinum- or taxane-containing chemotherapy regimen for locally advanced or metastatic disease. Patients with: prior pemetrexed or prior EGFRi therapy, more than two prior systemic anti-cancer therapies, uncontrolled cardiac disease or pleural/pericardial effusions, and those with the inability to interrupt aspirin or other non-steroidal anti-inflammatory agents for a 5-day period were excluded. Remaining eligibility requirements were as previously described . The study was approved by the institutional review boards of the University of Chicago and Ingalls Hospital and all participants provided written informed consent.
During a 2-week run-in, cetuximab was administered at an initial dose of 400 mg/m2 over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes. Typical dose adjustment and discontinuation criteria for cetuximab were used [1, 2]. Patients were randomized to treatment assignment at registration. On day 15, subjects assigned to Arm B received 500 mg/m2 pemetrexed after cetuximab. Pre-treatment folate and Vitamin B12 supplementation were provided in accordance with the package insert. In case of pemetrexed-related adverse events, doses were initially adjusted to 375 mg/m2 and again to 250 mg/m2 if required. Pemetrexed every 21 day cycles with weekly cetuximab continued until progression. Patients randomized to Arm A remained on cetuximab monotherapy until progression. Within 1–2 weeks of discontinuing cetuximab, these patients then crossed over to receive pemetrexed and appropriate supportive therapy.
Efficacy and safety evaluations
Tumor size was measured by computed tomography (CT) at baseline, on days 34–40, days 55–61, and days 76–82. Thereafter, it was measured every 34–40 days after previous CT scan while patients remained on study. Tumor measurements, responses, and disease progression were assessed using RECIST . The sum of the longest dimensions of each target lesion was tracked throughout the study and used to calculate the change in tumor size as a quantitative assessment of treatment effect [19, 20]. Baseline brain MR imaging was not performed. Patients who developed central nervous system symptoms were referred for imaging. Survival was confirmed with treating physicians and the Social Security Index when treating physicians were uncertain of date of death.
Rash rating scales used in this investigation
EGFR-Inhibitor induced rash scale
CTCAE Assessment scale
Isolated pustule or erythematous patch < 1 cm in diameter, on either face/head/neck or chest/back
Macular or papular eruption or erythema without associated symptoms
More than one erythematous patch or erythema and telangiectasia on either face/head/neck or chest/back
Macular or papular eruption or erythema with pruritus or other associated symptoms; localized desquamation or other lesions covering < 50% of body surface area
More than one pustule or papules on either face/head/neck or chest/back with no associated erythema or telangiectasia
Severe, generalized erythroderma or macular, papular or vesicular eruption; desquamation covering ≥ 50% body surface area
Both erythema/telangiectasia and pustules/papules limited to either face/head/neck or chest/back
Generalized exfoliative, ulcerative, or bullous dermatitis
Pustules or papules and erythema/telangiectasia present on both the face/head/neck region and the chest/back
Serum collection and analysis
Serum samples were collected at baseline and at subsequent time-points but only the baseline samples were analyzed. VeriStrat classifier was determined using coded, de-identified samples without any information regarding treatment assignment as previously described . Codes were returned to the principal investigator with assignments of “good”, “bad”, or “undetermined.” Undetermined samples were treated as missing data in all subsequent analyses.
Progression-free survival (PFS) time was calculated from the date of initial treatment on-study until determination of disease progression radiographically or clinically, or death regardless of attribution except for the analysis looking at the relationship with rash where PFS was calculated from day 22 of study therapy and two patients with progression or death prior to day 22 were excluded. Patients last known to be alive and progression-free were censored at the date of last CT scan without evidence of progression. Based on data available prior to the initiation of the trial, we expected a sample of 40 patients per treatment arm would achieve 80% power at a 0.1 significance level to detect an improvement in the progression-free survival rate at twelve weeks from 50% to 66%.
Progression-free and overall survival times across groups were estimated using the Kaplan-Meier procedure and compared with the log-rank test. In the comparison of overall survival between treatment arms, there was evidence of non-proportional hazards, and therefore the Wilcoxon-Gehan test  (which assigns greater weight to earlier time-points) rather than the log-rank test is presented. Results from Wilcoxon-Gehan tests are also reported for the landmark analyses.
Candidate biomarker evaluation
Given the rapidly changing definitions of standard therapies in NSCLC during the course of the study, it became clear in late 2007 that the enrollment goal would not be achieved, and so the focus of the investigation was reoriented to evaluation of candidate biomarkers in relation to the quantitative assessment of treatment effects with change in tumor size over the first 8 weeks of therapy. For the serum proteomic classifier, 10/43 (23%) evaluable patients did not have a pre-treatment serum marker classification. Fisher’s exact test was used for comparisons of treatment assignment, histology, and sex between those with serum marker data and those without.
During the course of the trial, independent groups conducted modeling studies to determine whether the change in the sum of the longest dimensions of target lesions for NSCLC at 8 weeks of therapy would be an acceptable primary endpoint for phase II clinical trials [19, 20, 22]. The primary motivations for use of Response Evaluation Criteria in Solid Tumors (RECIST) in phase II clinical trials and the shortcomings of response rate and progression-free survival as endpoints in small randomized trials have been well addressed elsewhere [19, 23]–. To maximize our sensitivity for detecting differences in performance of biomarkers for cetuximab, we applied the novel quantitative variable derived from the modeling studies, the log ratio of tumor size at 8 weeks of treatment versus baseline, as an experimental measure of treatment effect in the context of these data. The log of the ratio of the tumor size at the first evaluation on treatment (t1) to the baseline tumor size (t0) was used and defined as follows: log(t1/t0) = log(t1) – log(t0). As previously proposed, non-measurable negative outcomes are assigned poor outcome quantitative values and analyzed using rank-based procedures . Specifically, the one early death prior to the first CT scan on treatment was assumed to have the worst possible outcome, and the four subjects with brain MRIs confirming new metastases at the first evaluation were assumed to be tied with the worst progressor. The nonparametric Wilcoxon rank-sum test was used for comparison of change in tumor size between treatment and serum marker groups. A Spearman rank correlation coefficient was calculated to assess the association between change in tumor size and change in rash.
Baseline and disease characteristics for randomized, evaluable patients
Arm A (cetuximab alone)
Arm B (cetuximab + pemetrexed)
N = 20
N = 23
Sex: No. (%)
Ethnicity: No. (%)
Smoking history: No. (%)
Histology: No. (%)
A landmark analysis was performed to examine the association among PFS, OS and rash development by C1D8 (after 21 days of cetuximab therapy as in Gatzemeier, et al.) with the EIR and CTCAE scales. Using the threshold of rash of grade 1 or higher at any time, ignoring presence of baseline rash, gave the same results on both scales. Rash did not predict improved PFS (P = 0.91), but trended toward an association with improved OS (P = 0.06).
Change in tumor size and biomarker evaluations
We then tested the associations among this change in tumor size with the serum proteomic classifier and rash. “Good” serum predictor status was associated with more favorable changes in tumor size (P = 0.014) (Figure 3b).
This exploratory randomized phase II trial with a 2-week run-in of cetuximab monotherapy could inform future development of predictive biomarkers for EGFRi therapy in NSCLC. The biomarker development concepts implemented included: 1) piloting a modified version of the validated rosacea scale for EIR-rating, 2) use of modified quantitative assessment of tumor size changes to assess marker relationships, and 3) concomitant assessment of candidate markers, rash and serum proteomic profiling in the same patients. The EIR scale distributed rash ratings across a larger ordinal range than the conventional CTCAE rash scale; however this scaling did not strengthen the association with treatment outcomes beyond that of the categorical “rash vs. no rash” approach employed by Gatzemeier, et al. . The serum proteomic predictor was associated with treatment outcomes in this study of cetuximab and pemetrexed in the second-line treatment of NSCLC, although this finding might be due to confounding with treatment arm.
As a small trial, not meeting its intended accrual goals, there are clear limitations to this study. The setting of advanced NSCLC meant many patients deteriorated during or immediately after investigational treatment. As the value of information was not clear at the time of conducting the trial, we did not assess candidate molecular markers on patients’ tumors and we did not stratify the randomization by tumor histology. We had competing trials at that time that required information on tissue type for enrollment and a PS of only 0 or 1. This study unintentionally enrolled a typically more ill population with few never smokers (10%), fewer than usual women (under 40%), and many patients with non-adenocarcinoma or unknown histology (70%). The actual sample size meant only large effects, such as the benefit of immediate initiation of pemetrexed, could be detected with conventional measures such as progression-free and overall survival. The randomization did not effectively free the assessment from bias. This is highlighted by the unusually poor median-survival time in Arm A, 3.5 months is even low for a best-supportive care only trial. Arm A had fewer women, had patients with a higher median age, and more patients with serum proteome-profile-predicted “poor” outcomes with cetuximab monotherapy. It is therefore unclear the extent to which the treatment assignment versus the small sample size have biased the outcomes of this trial by study arm. The results are consistent with prior evidence of the value of timely treatment with pemetrexed in second-line treatment of NSCLC [29, 30]. Despite not reaching original accrual goals for the study, Arm B subjects, treated concurrently with pemetrexed and cetuximab, had better progression free and overall survival than Arm A subjects treated with sequential cetuximab followed by pemetrexed, reaching statistical significance for the latter. Notably, of the 20 evaluable patients who were randomized to Arm A, 10 did not maintain sufficiently good performance status to receive the pemetrexed after progression.
The EIR scale distributed ratings more broadly than CTCAE, but there is no evidence that this broader distribution will improve upon use of rash severity as a predictive marker for cetuximab efficacy in NSCLC. Serial skin biopsies were performed on a subset of patients in this study, but the heterogeneity of the specimens in terms of estimated volume, estimated total number of cells, enumerated EGFR-expressing cells and ratio of EGFR-expressing to total cells, as well as relative mRNA expression of candidate normalization molecules (data not shown) made semi-quantitative and correlative analyses impossible. Dose-to-rash studies with EGFRi have not revealed a significant benefit for increasing the severity of rash [31, 32]. Our data are consistent with the observations of others in larger trials, that incidence and not relative severity of EIR appears to be the pharmacodynamically relevant biomarker [7, 10].
Cetuximab monotherapy has no evident value in the treatment in unselected NSCLC patients in the second-line setting. Some could argue that cetuximab therefore has limited if any role in combination therapy. However, the data from Gatzemeier, et al. , suggest that a biomarker-based selection of patients who should receive cetuximab added to standard chemotherapy could yield improved outcomes over those reported for the cetuximab arm in the FLEX trial. This circumstance is increasingly common in oncology therapeutics, an agent that has limited but evident benefit in combination cannot be used ethically as monotherapy. Therefore, the early development monotherapy trials become an important opportunity with which to characterize candidate biomarkers and conduct preliminary validation and comparative estimate studies. In this “pure” setting, investigators can determine the typical time course, intensity, and interindividual variance in candidate markers. In a single disease, investigators can conduct preliminary comparisons to make estimates regarding which markers represent the best opportunities for future validation and qualification studies in large trials, including combination therapy trials.
For future qualification of candidate markers of EGFRi in the treatment of NSCLC, we propose that either the serum proteomic assay or incidence of rash be further evaluated as a means to exclude patients from receipt of cetuximab therapy. In patients who have the “poor” proteomic profile and those who fail to develop rash by 21 days of cetuximab therapy the likelihood of benefitting from cetuximab therapy appears low. In NSCLC, these markers, similar to the use of KRAS mutations in colorectal cancer, have reproducibly associated with absence of benefit from EGFRi therapy –[16, 33]. Our findings suggest future strategies to qualify these biomarkers for clinical use would be to demonstrate prospectively in a randomized trial that either or both markers effectively reduces the unnecessary, toxic, ineffective, and expensive use of cetuximab . Ideally, this study should help to identify safe and more effective alternatives for the patients who will not benefit from cetuximab therapy.
Typical phase II trials of combination therapy have had limited impact on the overall development of cancer therapeutics . Here we have demonstrated a strategy of: a brief monotherapy run-in, randomization, concurrent assessment of candidate biomarkers, and implementation of quantitative tumor size assessments as a potential means to make a local phase II trial more informative. The results of this study suggest that future development of either EIR or a serum proteomic predictor assay might focus on qualifying these markers to exclude prior to or early in treatment patients who have a low likelihood of benefiting from these expensive, potentially toxic therapies.
The authors wish to thank Drs. WanQing Liu and Aliya Husain for important intellectual contributions and Lijun He and Qudsia Arif for expert technical assistance.
This work was supported by Bristol-Myers Squibb through a contract for completion of the clinical and translational investigation to the University of Chicago. Additional support was provided by the University of Chicago Comprehensive Cancer Center. Biodesix provided blinded serum proteomic assay determinations. Dr. Maitland initiated this trial while enrolled in the Clinical Therapeutics Training Program (NIH/NIGMS T32 GM 007019).
- Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, et al: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009, 373 (9674): 1525-1531. 10.1016/S0140-6736(09)60569-9.View ArticlePubMedGoogle Scholar
- Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil S, Gorton S, et al: Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol. 2010, 28 (6): 911-917. 10.1200/JCO.2009.21.9618.View ArticlePubMedGoogle Scholar
- Fojo T, Grady C: How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009, 101 (15): 1044-1048. 10.1093/jnci/djp177.View ArticlePubMedPubMed CentralGoogle Scholar
- Joerger M, Matter-Walstra K, Fruh M, Kuhnel U, Szucs T, Pestalozzi B, Schwenkglenks M: Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol. 2011, 22 (3): 567-574. 10.1093/annonc/mdq431.View ArticlePubMedGoogle Scholar
- Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, Dakhil S, Hermann RC, Lynch TJ, Weber MR: Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2010, 28 (6): 918-927. 10.1200/JCO.2009.25.2890.View ArticlePubMedGoogle Scholar
- O'Byrne KJ, Gatzemeier U, Bondarenko I, Barrios C, Eschbach C, Martens UM, Hotko Y, Kortsik C, Paz-Ares L, Pereira JR, et al: Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol. 2011, 12 (8): 795-805. 10.1016/S1470-2045(11)70189-9.View ArticlePubMedGoogle Scholar
- Gatzemeier U, von Pawel J, Vynnychenko I, Zatloukal P, de Marinis F, Eberhardt WE, Paz-Ares L, Schumacher KM, Goddemeier T, O'Byrne KJ, et al: First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol. 2011, 12 (1): 30-37. 10.1016/S1470-2045(10)70278-3.View ArticlePubMedGoogle Scholar
- Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P: Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer. J Clin Oncol. 2004, 22 (16): 3238-3247. 10.1200/JCO.2004.11.057.View ArticlePubMedGoogle Scholar
- Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, et al: Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst. 2007, 99 (11): 838-846. 10.1093/jnci/djk195.View ArticlePubMedGoogle Scholar
- Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ: Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res. 2007, 13 (13): 3913-3921. 10.1158/1078-0432.CCR-06-2610.View ArticlePubMedGoogle Scholar
- Perrone F: Cetuximab in NSCLC: another trial needed. Lancet Oncol. 2011, 12 (1): 3-4. 10.1016/S1470-2045(10)70289-8.View ArticlePubMedGoogle Scholar
- Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, et al: A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer. 2010, 18 (4): 509-522. 10.1007/s00520-009-0744-x.View ArticlePubMedGoogle Scholar
- Wilkin J, Dahl M, Detmar M, Drake L, Liang MH, Odom R, Powell F: Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004, 50 (6): 907-912. 10.1016/j.jaad.2004.01.048.View ArticlePubMedGoogle Scholar
- Amann JM, Lee JW, Roder H, Brahmer J, Gonzalez A, Schiller JH, Carbone DP: Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol. 2010, 5 (2): 169-178. 10.1097/JTO.0b013e3181c8cbd9.View ArticlePubMedPubMed CentralGoogle Scholar
- Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, Roder J, Tsypin M, Herbst RS, Tsao AS, et al: VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer. 2010, 69 (3): 337-340. 10.1016/j.lungcan.2009.11.019.View ArticlePubMedGoogle Scholar
- Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, et al: Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev. 2010, 19 (2): 358-365. 10.1158/1055-9965.EPI-09-0937.View ArticlePubMedPubMed CentralGoogle Scholar
- Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, Tolcher AW, Villalona-Calero M, Sandler A, Chaudhuri T, et al: Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol. 2006, 24 (4): 552-562. 10.1200/JCO.2004.00.9720.View ArticlePubMedGoogle Scholar
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000, 92 (3): 205-216. 10.1093/jnci/92.3.205.View ArticlePubMedGoogle Scholar
- Karrison TG, Maitland ML, Stadler WM, Ratain MJ: Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst. 2007, 99 (19): 1455-1461. 10.1093/jnci/djm158.View ArticlePubMedGoogle Scholar
- Wang Y, Sung C, Dartois C, Ramchandani R, Booth BP, Rock E, Gobburu J: Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther. 2009, 86 (2): 167-174. 10.1038/clpt.2009.64.View ArticlePubMedGoogle Scholar
- Gehan EA: A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika. 1965, 52: 203-223.View ArticlePubMedGoogle Scholar
- Claret L, Andre V, De Alwis D, Bruno R: Modeling and simulation to assess the use of change in tumor size as primary endpoint in Phase II studies in oncology. Population Approach Group Europe. 2008, Marseille, France, Abstract 1386Google Scholar
- Fojo AT, Noonan A: RECIST: no longer the sharpest tool in the oncology clinical trials toolbox–reply to point. Cancer Res. 2012, 72 (20): 5150-10.1158/0008-5472.CAN-12-1989.View ArticlePubMedGoogle Scholar
- Fojo AT, Noonan A: Why RECIST works and why it should stay–counterpoint. Cancer Res. 2012, 72 (20): 5151-5157. 10.1158/0008-5472.CAN-12-0733. discussion 5158View ArticlePubMedGoogle Scholar
- Maitland ML, Bies RR, Barrett JS: A time to keep and a time to cast away categories of tumor response. J Clin Oncol. 2011, 29 (23): 3109-3111. 10.1200/JCO.2011.36.3887.View ArticlePubMedGoogle Scholar
- Rubinstein LV, Dancey JE, Korn EL, Smith MA, Wright JJ: Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?. J Natl Cancer Inst. 2007, 99 (19): 1422-1423. 10.1093/jnci/djm167.View ArticlePubMedGoogle Scholar
- Sharma MR, Maitland ML, Ratain MJ: Why RECIST works and why it should stay–reply to counterpoint. Cancer Res. 2012, 72 (20): 5158-10.1158/0008-5472.CAN-12-1988.View ArticlePubMedGoogle Scholar
- Sharma MR, Maitland ML, Ratain MJ: RECIST: no longer the sharpest tool in the oncology clinical trials toolbox–-point. Cancer Res. 2012, 72 (20): 5145-5149. 10.1158/0008-5472.CAN-12-0058. discussion 5150View ArticlePubMedGoogle Scholar
- Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009, 374 (9699): 1432-1440. 10.1016/S0140-6736(09)61497-5.View ArticlePubMedGoogle Scholar
- Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, et al: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012, 13 (3): 247-255. 10.1016/S1470-2045(12)70063-3.View ArticlePubMedGoogle Scholar
- Mita AC, Papadopoulos K, de Jonge MJ, Schwartz G, Verweij J, Mita MM, Ricart A, Chu QS, Tolcher AW, Wood L, et al: Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. Br J Cancer. 2011, 105 (7): 938-944. 10.1038/bjc.2011.332.View ArticlePubMedPubMed CentralGoogle Scholar
- Tejpar S, Peeters M, Humblet Y, Gelderblom H, Vermorken J, Viret F, Glimelius B, Ciardiello F, Kisker O, Van Cutsem E: Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data. ASCO Meet Abstr. 2007, 25 (18_suppl): 4037-Google Scholar
- Ding K, Pater J, Whitehead M, Seymour L, Shepherd FA: Validation of treatment induced specific adverse effect as a predictor of treatment benefit: a case study of NCIC CTG BR21. Contemp clin trials. 2008, 29 (4): 527-536. 10.1016/j.cct.2008.01.004.View ArticlePubMedGoogle Scholar
- Maitland ML, Hudoba C, Snider KL, Ratain MJ: Analysis of the yield of phase II combination therapy trials in medical oncology. Clin Cancer Res. 2010, 16 (21): 5296-5302. 10.1158/1078-0432.CCR-10-0669.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/5/prepub
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.